

C A N A D A W A T C H

Miraculins Signs Deal with Top Proteomics Group

Pharma Firm to Apply Leading Mass Spec Technology to R&D

Sarah Staples

Miraculins (Winnipeg, MB) signed a research agreement with the University of Manitoba to utilize the university's time-of-flight (TOF) mass spectrometry laboratory capabilities, under the direction of Kenneth Standing, Ph.D., and Werner Ens, Ph.D.

Miraculins, a biopharmaceutical company focused on proteomics R&D, says it will apply the technology in its research to identify disease-associated proteins.

Dr. Standing and long-time collaborator, Dr. Ens, together with MDS-Sciex (Mississauga, ON), report that they developed the prototype for the Qstar, a research tool designed to be more powerful than conventional TOF mass spectrometers. The instrument has been observed to provide dramatically improved performance, particularly when coupled with a laser-desorption source, which has also been developed in the

Manitoba laboratory.